Presentation is loading. Please wait.

Presentation is loading. Please wait.

Altered pathways in prostate cancer.

Published byVille-Veikko Leppänen Modified over 5 years ago

Similar presentations

Presentation on theme: "Altered pathways in prostate cancer."— Presentation transcript:

1 Altered pathways in prostate cancer.
Altered pathways in prostate cancer. (A) Metabolic and transcriptional analysis identified 27 pathways that were significantly altered in prostate cancer. (B) Overview of the pathway analysis based on metabolites alteration. (C) and (D) Gene set enrichment analysis of cysteine and methionine metabolism (NES = 1.48, p = .030), amino sugar and nucleotide sugar metabolism (NES = 1.58, p = .031). Shancheng Ren et al. Mol Cell Proteomics 2016;15: © 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Download ppt "Altered pathways in prostate cancer."

Similar presentations

Correlation of log-transformed signal intensity from two Affymetrix microarray hybridizations using platelet RNA. Plotted are those probesets with an average.

Correlation of log-transformed signal intensity from two Affymetrix microarray hybridizations using platelet RNA. Plotted are those probesets with an average.
Sequence alignment of C-terminal phosphorylated plant aquaporins

Sequence alignment of C-terminal phosphorylated plant aquaporins
Distribution of phosphorylation sites identified in the cytosolic phosphoproteome.A, numbers of approved phosphopeptides, previously phosphorylated peptides,

Distribution of phosphorylation sites identified in the cytosolic phosphoproteome.A, numbers of approved phosphopeptides, previously phosphorylated peptides,
Analysis of CD151 and CD147 as potential prostate cancer biomarkers.

Analysis of CD151 and CD147 as potential prostate cancer biomarkers.
Percentage of proteins identified in envelope membrane extracts according to the purification method and the number of transmembrane domains. Percentage.

Percentage of proteins identified in envelope membrane extracts according to the purification method and the number of transmembrane domains. Percentage.
Illustration of matched (FL-IFN-γR2/GFP and IFN-γR1/EBFP) and mismatched (IFN-γR1/EBFP and FL-IL-10R2/GFP) pairs of receptors. Illustration of matched.

Illustration of matched (FL-IFN-γR2/GFP and IFN-γR1/EBFP) and mismatched (IFN-γR1/EBFP and FL-IL-10R2/GFP) pairs of receptors. Illustration of matched.
Types of biomarkers/biosignatures to be used for cardiovascular disease. Types of biomarkers/biosignatures to be used for cardiovascular disease. There.

Types of biomarkers/biosignatures to be used for cardiovascular disease. Types of biomarkers/biosignatures to be used for cardiovascular disease. There.
Schematic of cellular role categories of theoretical (open bars) and identified proteins on a 2-D electrophoresis gel, pH 4–7 (black bars), in L. casei.

Schematic of cellular role categories of theoretical (open bars) and identified proteins on a 2-D electrophoresis gel, pH 4–7 (black bars), in L. casei.
Comparison of protein synthesis patterns of L

Comparison of protein synthesis patterns of L
Frequency distribution of the GRAVY of the theoretical proteins (open bars) and of 110 genes encoding proteins identified on a 2-D electrophoresis gel,

Frequency distribution of the GRAVY of the theoretical proteins (open bars) and of 110 genes encoding proteins identified on a 2-D electrophoresis gel,
Distributions of the ELDP values and Mascot scores for all protein identifications.a, frequency of ELDP value returned by correct (gray bars) and incorrect.

Distributions of the ELDP values and Mascot scores for all protein identifications.a, frequency of ELDP value returned by correct (gray bars) and incorrect.
Significantly enriched phosphorylation motifs from up-regulated phosphopeptides by Motif-X analysis. Significantly enriched phosphorylation motifs from.

Significantly enriched phosphorylation motifs from up-regulated phosphopeptides by Motif-X analysis. Significantly enriched phosphorylation motifs from.
Visual validation of the computational outputs.

Visual validation of the computational outputs.
Schematic representation of proteogenomic annotation strategy.

Schematic representation of proteogenomic annotation strategy.
Novel p53 target genes identified by RNA-Seq, pSILAC and ChIP-Seq.

Novel p53 target genes identified by RNA-Seq, pSILAC and ChIP-Seq.
Assay of NOS activity. Assay of NOS activity. Box show total NOS activity, the calcium-dependent activity of the constitutive isoforms of NOS (eNOS and.

Assay of NOS activity. Assay of NOS activity. Box show total NOS activity, the calcium-dependent activity of the constitutive isoforms of NOS (eNOS and.
Comparison of ROC plots for the PMF quality metrics using test dataset 2 (44 C. difficile proteins).a, ROC curves for coverage (open squares), MC (solid.

Comparison of ROC plots for the PMF quality metrics using test dataset 2 (44 C. difficile proteins).a, ROC curves for coverage (open squares), MC (solid.
Representative example of LAXIC performance for complex plant phosphoproteome. Representative example of LAXIC performance for complex plant phosphoproteome.A.

Representative example of LAXIC performance for complex plant phosphoproteome. Representative example of LAXIC performance for complex plant phosphoproteome.A.
Success rates in validation of antibodies from external providers

Success rates in validation of antibodies from external providers
Results from the Morris water task.

Results from the Morris water task.

Similar presentations

Ads by Google